Table 2.
Histological features of tissue specimens from patients who underwent a liver biopsy to evaluate the expression of R58/LAP-DP.
| NAFLD |
Viral hepatitis |
||
|---|---|---|---|
| Grade/Stage | (n) | Grade/Stage | (n) |
| Steatosis (%steatotic hepatocytes) | |||
| 0 (<5%) | 0 | ||
| 1 (5–33%) | 19 | ||
| 2 (>33–66%) | 16 | ||
| 3 (>66%) | 11 | ||
| Inflammation (foci/200x field) | Inflammation | ||
| 0 (no foci) | 2 | A0 (no activity) | 3 |
| 1 (<2 foci) | 21 | A1 (mild activity) | 25 |
| 2 (2–4 foci) | 17 | A2 (moderate activity) | 13 |
| 3 (>4 foci) | 6 | A3 (severe activity) | 2 |
| Ballooning | |||
| 0 (none) | 11 | ||
| 1 (few ballooned cells) | 17 | ||
| 2 (many cells/prominent ballooning) | 18 | ||
| NAS | |||
| 0–2 (simple steatosis) | 4 | ||
| 3–4 (borderline NASH) | 17 | ||
| 5–8 (definitive NASH) | 25 | ||
| Fibrosis | Fibrosis | ||
| 0 (no fibrosis) | 3 | F0 (no fibrosis) | 3 |
| 1a (mild perisinusoidal) | 11 | ||
| 1b (moderate perisinusoidal) | 7 | F1 (portal fibrosis w/o septa) | 18 |
| 1c (portal/periportal) | 0 | ||
| 2 (perisinusoidal and portal/periportal) | 5 | F2 (portal fibrosis with few septa) | 17 |
| 3 (bridging fibrosis) | 20 | F3 (numerous septa w/o cirrhosis) | 4 |
| 4 (cirrhosis) | 0 | F4 (cirrhosis) | 1 |
NAFLD, non-alcoholic fatty liver disease; NAS, NAFLD activity score; NASH, non-alcoholic steatohepatitis; w/o, without. Histological grading and staging of NAFLD and chronic viral hepatitis were performed according to the NASH Clinical Research Network criteria and the METAVIR scoring system [12, 13, 14].